{"filing":{"accession_number":"0001193125-26-337986","cik":"0001817241","ticker":"ARTV","company_name":"Artiva Biotherapeutics, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"artv-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526337986/artv-20260806.htm"},"events":[{"id":25614,"run_id":23247,"accession_number":"0001193125-26-337986","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) filed under Item 2.02. The press release discloses quarterly financial results including R\u0026D expenses ($21.9M), G\u0026A expenses ($5.0M), net loss ($25.0M), and cash position ($349.4M), along with condensed balance sheets and statements of operations. The disclosure is material to investors as it provides the registrant's financial performance and runway guidance (expected to fund operations into 2029).","company_name":"Artiva Biotherapeutics, Inc.","ticker":"ARTV","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26496,"accession_number":"0001193125-26-337986","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) filed under Item 2.02. The press release discloses quarterly financial results including R\u0026D expenses ($21.9M), G\u0026A expenses ($5.0M), net loss ($25.0M), and cash position ($349.4M), along with condensed balance sheets and statements of operations. The disclosure is material to investors as it provides the registrant's financial performance and runway guidance (expected to fund operations into 2029).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:17:15.626793+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26496,"accession_number":"0001193125-26-337986","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a clear earnings release for Q2 2026 (quarter ended June 30, 2026) filed under Item 2.02. The press release discloses quarterly financial results including R\u0026D expenses ($21.9M), G\u0026A expenses ($5.0M), net loss ($25.0M), and cash position ($349.4M), along with condensed balance sheets and statements of operations. The disclosure is material to investors as it provides the registrant's financial performance and runway guidance (expected to fund operations into 2029).","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:17:15.626793+00:00","company_name":"Artiva Biotherapeutics, Inc.","ticker":"ARTV","filing_date":"2026-08-06"}]}